Reboxetine: A novel antidepressant

Journal of Postgraduate Medicine

Volumn 49, Issue 4, 2003, Pages 373-375

  Kadhe, N G ^a   Chillar, A J ^a   Deshmukh, Y A ^a  

^a BYL NAIR CHARITABLE HOSPITAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; CITALOPRAM; CYCLOSPORIN; CYTOCHROME P450 3A4; DESIPRAMINE; DOPAMINE; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; LITHIUM; MACROLIDE; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; NORADRENALIN; PAROXETINE; REBOXETINE; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; ANTIDEPRESSANT AGENT; MORPHOLINE DERIVATIVE;

AGITATION; CLINICAL TRIAL; CONSTIPATION; DEPRESSION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLASSIFICATION; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERTENSION; NERVOUSNESS; ORTHOSTATIC HYPOTENSION; REVIEW; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SOMNOLENCE; STEADY STATE; TREMOR; URINARY EXCRETION; URINE RETENTION; WEIGHT GAIN; XEROSTOMIA; ARTICLE;

ANTIDEPRESSIVE AGENTS; HUMANS; MORPHOLINES;

EID: 1542644129     PISSN: 00223859     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (18)

1. Akisal HS, Blazer DG, Kelsoe ME, et al. Mood Disorders In: Sadock BJ, Sadock VA, editors. Kaplan and Sadock's Comprehensive Textbook of Psychiatry. 7th edn. Lippincott Williams & Wilkins; 2000. pp. 1284-440.
2. De Battista C, Schatzberg AF. Other Biological and Pharmacological therapies In: Sadock BJ, Sadock VA, editors. Kaplan and Sadock's Comprehensive Textbook of Psychiatry. 7th edn. Lippincott Williams & Wilkins; 2000. pp. 2527.
3. Zydus Neurosciences. Narebox. Product Monograph.
4. Delgado PL, Moreno FA. Role of norepinephrine in depression. J Clin Psychiatry 2000;61:5-12.
5. Kent JM. SNaRIs, NaSSAs and NaRIs: new agents for the treatment of depression. Lancet 2000;355:911-8.
6. Holm KJ, Spencer CM. Reboxetine A Review of its Use in Depression. CNS Drugs 1999;12:65-83.
7. Martin Dale. The complete drug reference. Parfitt K, editor. 32nd edn. Pharmaceutical Press; 1999. pp. 307.
8. Montgomery SA. Chairmans overview. The place of reboxetine in antidepressant therapy. J Clin Psychiatry 1998;59:26-9.
9. Massana J, Moller HJ, Burrows GD, Montenegro RM. Reboxetine: a double-blind comparison with fluoxetine in major depressive disorder. Int Clin Psychopharmacol 1999;14:73-80.
10. Venditti LN, Arcelus A, Birnbaum H, Greenberg P, Barr CE, Rowland C, et al. The impact of antidepressant use on social functioning: reboxetine versus fluoxetine. Int Clin Psychopharmacol 2000;15:279-89.
11. Berzewski H, Van Moffaert M, Gagiano CA. Efficacy and tolerability of reboxetine compared with imipramine in a double-blind study in patients suffering from major depressive offsodes. Eur Neuropsychopharmacol 1997;Suppl 1:S37-47; (discussion S71-3).
12. Tanum L Reboxetine: tolerability and safety profile in patients with major depression. Acta Psychiatr Scand Suppl 2000;402:37-40.
13. AndreoliV, Carbognin G, Abati A, Vantini G. Reboxetine in the treatment of depression in the elderly: pilot study. J Geriatr Psychiatry Neurol 1999;12:206-10.
14. Larrosa O, de la Llave Y, Bario S, Granizo JJ, Garcia-Borreguero D. Stimulant and anti cataplectic effects of reboxetine in patients with narcolepsy: a pilot study Sleep 2001;24:282-5.
15. Dannon PN, Iancu I, Grunhaus L. The efficacy of reboxetine in the treatment-refractory patients with panic disorder: an open label study. Human Psychopharmacol 2002;17:329-33.
16. Lemke MR. Effect of reboxetine on depression in Parkinson's disease patients. J Clin Psychiatry 2002;63:300-4.
17. Healy D. Reboxetine: its effects as measured by the Social Adaptation Self evaluation Scale. Acta Psychiatr Scand Suppl 2000;402: 45-51.
18. Massana J, Moller HJ, Burrows GD, Montenegro RM. Reboxetine: a double blind comparison with fluoxetine in major depressive disorder. Int Clin Psychopharmacol 1999;14:73-80.